Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.
Abraham WT, Lindenfeld J, Ponikowski P, Agostoni P, Butler J, Desai AS, Filippatos G, Gniot J, Fu M, Gullestad L, Howlett JG, Nicholls SJ, Redon J, Schenkenberger I, Silva-Cardoso J, Störk S, Krzysztof Wranicz J, Savarese G, Brueckmann M, Jamal W, Nordaby M, Peil B, Ritter I, Ustyugova A, Zeller C, Salsali A, Anker SD. Abraham WT, et al. Among authors: nordaby m. Eur Heart J. 2021 Feb 11;42(6):700-710. doi: 10.1093/eurheartj/ehaa943. Eur Heart J. 2021. PMID: 33351892 Clinical Trial.
Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.
Oldgren J, Steg PG, Hohnloser SH, Lip GYH, Kimura T, Nordaby M, Brueckmann M, Kleine E, Ten Berg JM, Bhatt DL, Cannon CP. Oldgren J, et al. Among authors: nordaby m. Eur Heart J. 2019 May 14;40(19):1553-1562. doi: 10.1093/eurheartj/ehz059. Eur Heart J. 2019. PMID: 30793734 Free PMC article. Clinical Trial.
Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial.
Lip GYH, Mauri L, Montalescot G, Ozkor M, Vardas P, Steg PG, Bhatt DL, Hohnloser SH, Miede C, Nordaby M, Brueckmann M, Kreuzer J, Kimura T, Oldgren J, Ten Berg JM, Cannon CP. Lip GYH, et al. Among authors: nordaby m. Am Heart J. 2019 Jun;212:13-22. doi: 10.1016/j.ahj.2019.02.006. Epub 2019 Mar 1. Am Heart J. 2019. PMID: 30928824 Clinical Trial.
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.
Verma S, Dhingra NK, Butler J, Anker SD, Ferreira JP, Filippatos G, Januzzi JL, Lam CSP, Sattar N, Peil B, Nordaby M, Brueckmann M, Pocock SJ, Zannad F, Packer M; EMPEROR-Reduced trial committees and investigators. Verma S, et al. Among authors: nordaby m. Lancet Diabetes Endocrinol. 2022 Jan;10(1):35-45. doi: 10.1016/S2213-8587(21)00292-8. Epub 2021 Nov 30. Lancet Diabetes Endocrinol. 2022. PMID: 34861154
Empagliflozin in Black Versus White Patients With Heart Failure: Analysis of EMPEROR-Pooled.
Verma S, Dhingra NK, Butler J, Anker SD, Pedro Ferreira J, Filippatos G, Januzzi JL, Lam CSP, Sattar N, Pfarr E, Nordaby M, Brueckmann M, Pocock SJ, Zannad F, Packer M; EMPEROR-Pooled Trial Committees and Investigators. Verma S, et al. Among authors: nordaby m. Circulation. 2023 Jan 3;147(1):101-104. doi: 10.1161/CIRCULATIONAHA.122.062644. Epub 2022 Nov 7. Circulation. 2023. PMID: 36342827 No abstract available.
Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity.
Bianzano S, Nordaby M, Plum-Mörschel L, Peil B, Heise T. Bianzano S, et al. Among authors: nordaby m. Diabetes Obes Metab. 2023 Mar;25(3):832-843. doi: 10.1111/dom.14932. Epub 2022 Dec 22. Diabetes Obes Metab. 2023. PMID: 36478142 Free PMC article. Clinical Trial.
Presence of Peripheral Artery Disease Is Associated With Increased Risk of Heart Failure Events: Insights From EMPEROR-Pooled.
Verma S, Dhingra NK, Bonaca MP, Butler J, Anker SD, Ferreira JP, Filippatos G, Januzzi JL, Lam CSP, Sattar N, Iwata T, Nordaby M, Brueckmann M, Pocock SJ, Packer M; EMPEROR Trials Committees and Investigators. Verma S, et al. Among authors: nordaby m. Arterioscler Thromb Vasc Biol. 2023 Jul;43(7):1334-1337. doi: 10.1161/ATVBAHA.123.319156. Epub 2023 May 18. Arterioscler Thromb Vasc Biol. 2023. PMID: 37199158 Free PMC article. No abstract available.
Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE.
Ferreira JP, Blatchford JP, Teerlink JR, Kosiborod MN, Angermann CE, Biegus J, Collins SP, Tromp J, Nassif ME, Psotka MA, Comin-Colet J, Mentz RJ, Brueckmann M, Nordaby M, Ponikowski P, Voors AA. Ferreira JP, et al. Among authors: nordaby m. Eur J Heart Fail. 2023 Oct;25(10):1797-1805. doi: 10.1002/ejhf.2982. Epub 2023 Aug 22. Eur J Heart Fail. 2023. PMID: 37540060 Free article. Clinical Trial.
Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF: Post-Hoc Analysis of EMPEROR-Reduced.
Dhingra NK, Verma S, Butler J, Anker SD, Ferreira JP, Filippatos G, Januzzi JL, Lam CSP, Sattar N, Zaremba-Pechmann L, Böhm M, Nordaby M, Brueckmann M, Pocock SJ, Zannad F, Packer M; EMPEROR-Reduced Trial Committees and Investigators. Dhingra NK, et al. Among authors: nordaby m. JACC Heart Fail. 2024 Jan;12(1):35-46. doi: 10.1016/j.jchf.2023.06.036. Epub 2023 Sep 13. JACC Heart Fail. 2024. PMID: 37715769 Free article. Clinical Trial.
35 results